Evidence map›Paper›PMID 37402738›Full record

ArticleScientific reports2023

The engineered single guide RNA structure as a biomarker for gene-editing reagent exposure.

Emmarie C Ryan, Leslie M Huggins, Joshua D Podlevsky

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 74% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Emmarie C RyanMolecular and Microbiology, Sandia National Laboratories, Albuquerque, NM, 87185, USA.
Leslie M HugginsComputational Biology and Biophysics, Sandia National Laboratories, Albuquerque, NM, 87185, USA.
Joshua D PodlevskyMolecular and Microbiology, Sandia National Laboratories, Albuquerque, NM, 87185, USA. jpodle@sandia.gov.
Sandia National Laboratories · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR arrays and CRISPR-associated (Cas) proteins comprise a prevalent adaptive immune system in bacteria and archaea. These systems defend against exogenous parasitic mobile genetic elements. The adaption of single effector CRISPR-Cas systems has massively facilitated gene-editing due to the reprogrammable guide RNA. The guide RNA affords little priming space for conventional PCR-based nucleic acid tests without foreknowledge of the spacer sequence. Further impeding detection of gene-editor exposure, these systems are derived from human microflora and pathogens (Staphylococcus pyogenes, Streptococcus aureus, etc.) that contaminate human patient samples. The single guide RNA-formed from the CRISPR RNA (crRNA) and transactivating RNA (tracrRNA)-harbors a variable tetraloop sequence between the two RNA segments, complicating PCR assays. Identical single effector Cas proteins are used for gene-editing and naturally by bacteria. Antibodies raised against these Cas proteins are unable to distinguish CRISPR-Cas gene-editors from bacterial contaminant. To overcome the high potential for false positives, we have developed a DNA displacement assay to specifically detect gene-editors. We leveraged the single guide RNA structure as an engineered moiety for gene-editor exposure that does not cross-react with bacterial CRISPRs. Our assay has been validated for five common CRISPR systems and functions in complex sample matrices.

Indexed as

BacteriaRNA, Guide, CRISPR-Cas SystemsBiomarkersCRISPR-Cas SystemsGene EditingHumansRNABiomarkersRNARNA, Guide, CRISPR-Cas Systems

Identifiers

PMID37402738
PMCPMC10319717
OpenAlexW4383103339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.